[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100421315":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":43,"locations":50,"responsibleParty":67,"collaborators":48,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":48,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":48,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":48,"overallStatus":53,"whyStopped":48,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"bumetanide group","EXPERIMENTAL","Bumetanide a dose of 0.5 mg twice per day",[13],"Drug: Bumetanide",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo twice daily",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Bumetanide","bumetanide 0.5 mg twice daily",[9],[27],"burinex",{"type":22,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"placebo tablets twice daily",[15],[32],"Placebo treatment",[34,38,41],{"name":35,"affiliation":36,"role":37},"Osama Elagamy, Prof","Pediatrics Department- Kafr-Elsheikh University","PRINCIPAL_INVESTIGATOR",{"name":39,"affiliation":36,"role":40},"Abeer Salamah, Dr","STUDY_DIRECTOR",{"name":42,"affiliation":36,"role":37},"Esraa Shaker, Msc",[44],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},"Sherief Abd-Elsalam, ass. prof.","CONTACT","00201147773440",null,"sheriefabdelsalam@yahoo.com",[51],{"facility":52,"status":53,"city":54,"state":48,"zip":48,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Sherief Abd-Elsalam","RECRUITING","Tanta","Egypt","EG",{"type":58,"coordinates":59},"Point",[60,61],31.00192,30.78847,{"lat":61,"lon":60},[64],{"name":65,"role":46,"phone":66,"phoneExt":48,"email":49},"Sherief Abd-Elsalam, Ass. Prof.","00201009221243",{"type":68,"investigatorFullName":52,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":48,"oldOrganization":48},"SPONSOR_INVESTIGATOR","Ass. Prof. Tropical Medicine","100421315","phase-3-role-of-bumetanide-in-treatment-of-autism-100421315",false,"NCT04766177","Role of Bumetanide in Treatment of Autism","Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children","Inclusion Criteria:\n\n1. All patients with ASD diagnosed by CARS rating Scale⩾30.\n2. Age of patients range between (3-12) years.\n\nExclusion Criteria:\n\n* Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).","ALL","3 Years","12 Years",{"count":81,"type":82},80,"ESTIMATED","INTERVENTIONAL",[85],"PHASE3","Role of bumetanide in Autism",[88],"Autism","2021-02-19",{"date":91,"type":92},"2021-02-23","ACTUAL",{"date":94,"type":92},"2021-01-01",{"date":96,"type":82},"2030-12-01",{"name":52,"class":6},1]